Atlas Trials

Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy

Clinical trial NCT07400250 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07400250
Sponsor
Peking Union Medical College Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia (ITP)
Start date
2026-04-01
Primary completion
2026-10-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.